Herceptin is approved for the treatment of early-stage breast cancer that is Human
Epidermal growth factor
Receptor 2-positive (HER2+) and
has spread into the lymph nodes, or is HER2+ and
has not spread into the lymph nodes. If it has not spread into the
lymph nodes, the cancer needs to be estrogen receptor/progesterone
receptor
(ER/PR)-negative or have one high risk feature.* Herceptin can be
used in several different ways:
- As part of a treatment course including the chemotherapy drugs Adriamycin® (doxorubicin), Cytoxan® (cyclophosphamide), and either Taxol® (paclitaxel) or Taxotere® (docetaxel). This treatment course is known as "AC→TH."
- With the chemotherapy drugs Taxotere and Paraplatin® (carboplatin). This treatment course is known as "TCH."
- Alone after treatment with multiple other therapies, including an anthracycline (Adriamycin)-based therapy (a type of chemotherapy).
*High risk is defined as ER/PR-positive with one of the following features: tumor size
>2 cm, age <35 years, or tumor grade 2 or 3.
Adriamycin is a registered trademark of Pharmacia, Inc.
Cytoxan, Taxol, and Paraplatin are registered trademarks of Bristol-Myers Squibb Company.
Taxotere is a registered trademark of sanofi-aventis U.S. LLC.
Adriamycin is a registered trademark of Pharmacia, Inc.
Cytoxan, Taxol, and Paraplatin are registered trademarks of Bristol-Myers Squibb Company.
Taxotere is a registered trademark of sanofi-aventis U.S. LLC.
Metastatic Breast Cancer
Herceptin has 2 approved uses in metastatic breast cancer:
Taxol is a registered trademark of Bristol-Myers Squibb Company.
Gastric Cancer
Herceptin is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil),
for the treatment of HER2+ metastatic cancer of the stomach or gastroesophageal junction (where the esophagus
meets the stomach) in patients who have not received prior treatment for their metastatic disease.
No comments:
Post a Comment